dongYan Dong, Ph.D.
Professor

ydong@tulane.edu

Research Interests:

Dr. Dong has a long-standing interest in prostate cancer particularly in altered androgen receptor signaling in castration-resistant prostate cancer and mechanisms and efficacies of candidate prostate cancer interventions. Despite the recent development and FDA approval of new hormone therapy drugs for metastatic castration-resistant prostate cancer, disease progression after hormone therapies remains the most critical challenge in the clinical management of prostate cancer. Emerging evidences indicate that prostate cancers can adapt to all current hormone therapies by signaling through constitutively-active androgen receptor splice variants that lack the ligand-binding domain. We are currently characterizing how these splice variants are generated and their mechanisms of action. We are also developing drugs/regimens to inhibit these splice variants for more effective treatment of advanced prostate cancer.

Publications:

  • Y Zhan, G Zhang, X Wang, Y Qi, S Bai, D Li, T Ma, O Sartor, EK Flemington, H Zhang, P Lee, and Y Dong. (2017) Interplay between cytoplasmic and nuclear androgen receptor splice variants mediate castration resistance. Molecular Cancer Research, 15, 59-68. PMID: 27671337. Featured in the "Molecular Cancer Research Highlights: Selected Articles from This Issue" with a figure.

  • S Cao, Y Zhan, and Y Dong. (2016) Emerging data on androgen receptor splice variants in prostate cancer. Endocrine-Related Cancer, Invited review. 23:T199-T210. PMCID:PMC5107136. Featured in “Uro Today”.

  • D Xu, Y Zhan, Y Qi, B Cao, S Bai, W Xu, SS Gambhir, P Lee, O Sartor, EK Flemington, H Zhang, CD Hu, and Y Dong.  (2015) Androgen receptor splice variants dimerize to transactivate target genes. Cancer Research, 75, 3663-3671. PMCID:PMC4558376. Featured in “MDLinx”, “Just Cancer News”, “BioWorld from Thomson Reuters”.  Editorial: Emmanuel S. Antonarakis and Jun Luo. (2015) AR splice variant dimerization - clinical implications Nature Reviews Urology, 12, 431-433.

  • B Cao, Y Qi, G Zhang, D Xu, Y Zhan, X Alvarez, Z Guo, X Fu, SR Plymate, O Sartor, H Zhang, and Y Dong. (2014) Androgen Receptor Splice Variants Activating the Full-Length Receptor in Mediating Resistance to Androgen-Directed Therapy.  Oncotarget, 5, 1646-56.  PMCID:PMC4039237.

  • Y Zhan, B Cao, Y Qi, S Liu, Q Zhang, W Zhou, D Xu, H Lu, O Sartor, W Kong, H Zhang, and Y Dong. (2013) Methylselenol Prodrug Enhances MDV3100 Efficacy for Treatment of Castration-Resistant Prostate Cancer.  International Journal of Cancer, 133, 2225-33.  PMCID:PMC3750963.  Featured in “MDLinx”.

  • B Cao, X Liu, J Li, S Liu, Y Qi, Z Xiong, A Zhang, T Wiese, X Fu, J Gu, PS Rennie, O Sartor, BR Lee, C Ip, L Zhao, H Zhang, and Y Dong. (2013) 20(S)-Protopanaxadiol-aglycone Downregulation of the Full-length and Splice Variants of Androgen Receptor.  International Journal of Cancer, 132, 1277–1287.   PMCID:PMC3509250.